We hypothesised that hyaluronan (HA) degradation by PEGPH20 may alter tumour viscoelasticity measured by MR elastography (MRE). MRE was performed before and after PEGPH20 in three orthotopic breast tumour models (4T1, 4T1/HAS3 and MDA-MB-231 LM2-4). Viscoelastic properties did not change following PEGPH20 in 4T1 and 4T1/HAS3 tumours. However, a dramatic PEGPH20-induced increase in tumour viscoelasticity was seen in MDA-MB-231 LM2-4 tumours, likely the result of collagen network rearrangement and not HA degradation alone. Although MRE is unlikely to provide a robust biomarker of PEGPH20 response, these data clearly demonstrate that MRE-derived biomarkers can inform on increased tumour stiffness in vivo.
This abstract and the presentation materials are available to members only; a login is required.